CD4 and mature T-cell and NK-cell non-Hodgkin lymphoma: After the humanized anti-CD4 mAb zanolimumab was studied in Phase II trials in both CTCL [85] and PTCL [86] with inadequate response rates, efforts have since turned to anti-CD4 CAR therapies.